



NDA 022474/S-004

**SUPPLEMENT APPROVAL**

Laboratoire HRA Pharma  
c/o Pacific-Link Regulatory Consulting  
Attention: Richard E. Lowenthal, MSc, MBA  
President  
8195 Run of the Knolls Ct.  
San Diego, CA 92172

Dear Mr. Lowenthal:

Please refer to your Supplemental New Drug Application (sNDA) dated and received September 12, 2013, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for **ella** (ulipristal acetate) Tablets.

We acknowledge receipt of your amendments dated May 16 and June 3, 2014.

This "Prior Approval Supplement" supplemental new drug application provides for changes based on results of several studies that evaluated drug-drug interactions and the pharmacokinetics of **ella** in lactating women and transfer into breast milk. These changes were made to the following sections of the prescribing information; conforming language was also added to the patient labeling:

- Addition of a new section to Warnings and Precautions recommending against use of **ella** concomitantly with CYP3A4 inducers
- Changes to Section 7, Drug Interactions, and to Subsections 7.1 and 7.3
- Revision of Section 8.3, Nursing Mothers, to recommend against use of **ella** by breastfeeding women, and conforming language in Section 17, Patient Counseling Information
- Addition of new information to Section 12.3, Pharmacokinetics

**APPROVAL & LABELING**

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

## **CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert and text for the patient package insert), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

## **REQUIRED PEDIATRIC ASSESSMENTS**

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

## **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Jennifer Mercier, Chief, Project Management Staff, at (301) 796-0957.

Sincerely,

*{See appended electronic signature page}*

Audrey Gassman, M.D.  
Deputy Director  
Division of Bone, Reproductive and Urologic Products  
Office of Drug Evaluation III  
Center for Drug Evaluation and Research

ENCLOSURE:  
Content of Labeling

-----  
**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**  
-----

/s/  
-----

AUDREY L GASSMAN  
06/12/2014